Sirolimus-tacrolimus combination immunosuppression

Lancet

Volumn 355, Issue 9201, 2000, Pages 376-377

  McAlister, Vivian C ^a   Gao, Zuhua ^a   Peltekian, Kevork ^a   Domingues, Javier ^a   Mahalati, Kamrar ^a   MacDonald, Allan S ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME;

EID: 0034728055     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03882-9     Document Type: Article

References (5)

1. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
2. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
3. Sirolimus: A potent new immunosuppressant for liver transplantation
4. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells
5. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonist but produce extended graft survival in cardiac transplantation in the rat